ArticleBMC cardiovascular disorders2025
Knockdown of JunB alleviates LPS-induced H9C2 cardiomyocyte injury and sepsis-induced myocardial injury by activating the PI3K/Akt/mTOR signaling pathway.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJunB expression found to be upregulated in sepsis-induced myocardial injury (SIMI) tissue samples, yet its role in this disease remains unexplored. This study aimed to investigate the role and underlying mechanism of JunB in SIMI.
methodsIn vitro and in vivo SIMI models were established by stimulating H9C2 cardiomyocytes with lipopolysaccharide (LPS) and inducing sepsis via cecal ligation and puncture (CLP) in mice, respectively. In both models, JunB expression was modulated, and several key parameters were evaluated, including apoptosis, levels of inflammatory cytokines (IL-6 and TNF-α), oxidative stress, ferroptosis, and endoplasmic reticulum (ER) stress. Additionally, the activation of PI3K/Akt/mTOR signaling pathway was examined. To confirm the mechanism of JunB, a PI3K/Akt-specific inhibitor, LY294002, was applied in the cell model.
resultsJunB expression was elevated in both SIMI models. In vitro, JunB downregulation significantly increased cell viability, SOD activity, and GPX4 expression, while it decreased IL-6 and TNF-α levels, reduced apoptosis, ROS accumulation, MDA content, and ATF6 expression. In contrast, JunB upregulation produced the opposite effects. In vivo, downregulation of JunB reduced serum levels of myocardial injury markers (CK-MB and cTnT), improved myocardial damage, and decreased myocardial inflammation, apoptosis, oxidative stress, ferroptosis, and ER stress. JunB knockdown activated the PI3K/Akt/mTOR pathway in both models. LY294002 treatment reversed the protective effects of JunB silencing on LPS-induced cell injury.
conclusionsKnockdown of JunB alleviates sepsis-induced myocardial inflammation, apoptosis, oxidative stress, ferroptosis, and ER stress by activating the PI3K/Akt/mTOR signaling pathway. This suggests that JunB may be a potent therapeutic target for SIMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.